<p>Novo Nordisk’s CEO, <strong>Mike Doustdar</strong>, is a 33-year veteran of the company who previously led its entire international organization. This experience gives him a deep insider’s perspective, making his insights particularly valuable.</p>
<p>This article distills his key ideas into three main areas:</p>
<ul>
    <li>How a leading pharmaceutical company executes a multi-billion-dollar corporate strategy.</li>
    <li>The surprising consumer-driven forces reshaping the obesity drug market.</li>
    <li>What these shifts signal for the future of how medicine is paid for globally.</li>
</ul>

<div class="image-container">
    <img src="assets/images/JPM2026-Novo-Nordisk-CEO-Insights.png" alt="Novo Nordisk CEO Mike Doustdar">
    <p class="image-caption">Novo Nordisk CEO Mike Doustdar sharing insights on the future of pharma</p>
</div>

<h3>1. A Disciplined Approach to Growth</h3>
<p>Recently, Novo Nordisk engaged in a high-profile bidding war to acquire <strong>Metsera</strong>, which was ultimately acquired by rival <strong>Pfizer</strong>. Doustdar viewed the experience not as a loss, but as a learning opportunity—and a powerful demonstration of a core principle: financial discipline.</p>
<p>This was not a case of losing; it was a deliberate choice not to overpay. The most compelling evidence of this discipline comes from Doustdar himself: “Our very first bid was <strong>$10 billion</strong>. Our very last bid, 16 times later, was <strong>$10 billion</strong>.” Their refusal to budge reveals a mature strategy focused on strategic fit and long-term shareholder value, rather than winning a bidding war for its own sake.</p>

<h4>Novo Nordisk’s Patient-First Acquisition Strategy</h4>
<p>This discipline is embedded in a clear, patient-focused process that precedes any price negotiation:</p>
<ul>
    <li><strong>Start with the patient need:</strong> Before examining deals, the company first quantifies the number of patients it aims to treat in its core areas, such as diabetes and obesity. This patient-centric view anchors the entire strategy.</li>
    <li><strong>Assess the internal pipeline:</strong> Next, Novo Nordisk evaluates the drugs already in development. This highlights existing strengths and, more importantly, strategic gaps.</li>
    <li><strong>Scan the market:</strong> Only then does the company look externally for assets to acquire, seeking technologies that complement its pipeline, are scientifically superior, or can reach the market faster.</li>
    <li><strong>Analyze the data:</strong> Scientific rigour is paramount. Any potential deal is evaluated based on the strength and quality of the clinical evidence.</li>
    <li><strong>Set the price:</strong> After completing all prior steps, the company determines what the asset is truly worth to Novo Nordisk. This ensures pricing is grounded in scientific value and strategic need, not market hype.</li>
</ul>

<h3>2. The Obesity Market: A New World for Pharma</h3>
<p>According to Doustdar, the obesity drug market is behaving less like a traditional prescription business and more like a fast-moving consumer goods (FMCG) market. This represents a fundamental shift, forcing a traditionally science-driven industry to build new capabilities in consumer marketing, supply chain management, and direct-to-consumer digital engagement.</p>

<h4>The Surprising Rise of Online Sales</h4>
<p>Novo Nordisk was surprised to discover that the primary growth engine for its obesity drugs was not traditional insurance plans, but online “e-health” channels. This shift was driven by a massive gap between insurance coverage and real-world access:</p>
<ul>
    <li>Approximately <strong>55 million</strong> people in the U.S. had insurance coverage for a product like Novo Nordisk’s <strong>Wegovy®</strong> (semaglutide).</li>
    <li>Due to restrictions and administrative barriers, only <strong>1–2 million</strong> were actually able to obtain the drug through insurance.</li>
</ul>
<p>This bottleneck created a large population of frustrated yet highly motivated consumers who bypassed the traditional system and sought treatment directly from online providers.</p>

<h4>Lessons from Compounders</h4>
<p>The company also learned important lessons from compounders—entities that manufacture and sell unofficial versions of branded drugs. Doustdar acknowledges that these competitors revealed two critical market truths:</p>
<ul>
    <li><strong>Price Sensitivity:</strong> Compounders demonstrated that a vast, previously untapped market exists. Consumers unwilling or unable to pay $3.99–$4.99 for the branded product were willing to pay <strong>$1.99</strong> for a knockoff.</li>
    <li><strong>Consumer Engagement:</strong> These online players were often more effective at managing direct consumer dialogue and offered greater flexibility in dosing.</li>
</ul>

<h4>Expanding the Market, Not Just a Market Share War</h4>
<p>Although Novo Nordisk is in fierce competition with <strong>Eli Lilly</strong>, Doustdar emphasizes that the primary objective is to expand the total market.</p>
<p>Of an estimated <strong>100 million</strong> people in the U.S. who could benefit from obesity treatments, only <strong>10–15 million</strong> are currently being treated. The remaining <strong>85 million</strong> represent a vast, underserved population. The true opportunity lies in reaching this majority, not just competing over the current minority.</p>

<h3>3. The Future of Payment: The Growing Role of the Consumer</h3>
<p>Doustdar predicts a fundamental shift in how medicines are paid for over the next decade. As drug R&D costs continue to rise and government healthcare systems face increasing financial pressure, a new solution is emerging: <strong>patients will pay for a larger share of their own medications.</strong></p>
<p>This "cash pay" model is already gaining traction in the U.S. obesity market and may be a leading indicator of its spread into other therapeutic areas.</p>

<h4>Navigating the Global Landscape</h4>
<p>Drug pricing and market access dynamics vary significantly across regions:</p>

<table style="width:100%; border-collapse: collapse; margin: 20px 0; font-size: 15px;">
  <thead>
    <tr style="background-color: #f6f8fa; text-align: left;">
      <th style="padding: 12px; border: 1px solid #d0d7de;">Comparison</th>
      <th style="padding: 12px; border: 1px solid #d0d7de;">U.S. Market View</th>
      <th style="padding: 12px; border: 1px solid #d0d7de;">European Market View</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="padding: 12px; border: 1px solid #d0d7de;"><strong>Pricing Perception</strong></td>
      <td style="padding: 12px; border: 1px solid #d0d7de;">Drug prices are perceived as very high.</td>
      <td style="padding: 12px; border: 1px solid #d0d7de;">Drug prices are often viewed as too low.</td>
    </tr>
    <tr>
      <td style="padding: 12px; border: 1px solid #d0d7de;"><strong>System Structure</strong></td>
      <td style="padding: 12px; border: 1px solid #d0d7de;">High cost of operating and doing business.</td>
      <td style="padding: 12px; border: 1px solid #d0d7de;">Relies on tax revenue; relatively few access barriers for patients.</td>
    </tr>
  </tbody>
</table>

<h3>Conclusion</h3>
<p>Mike Doustdar’s insights offer a roadmap to the forces shaping the future of the pharmaceutical industry.</p>
<ul>
    <li><strong>Discipline Drives Decisions:</strong> Successful pharma leaders do not make multi-billion-dollar bets impulsively. They follow rigorous, patient-focused processes and maintain discipline, even when it means walking away from high-profile deals.</li>
    <li><strong>The Consumer is the New Power Player:</strong> Direct consumer demand and online sales are fundamentally reshaping a major prescription drug market. Companies must master direct-to-consumer engagement.</li>
    <li><strong>The Goal is to Grow the Whole Pie:</strong> In a massive, underserved market like obesity, the strategic imperative is to expand the entire market. Reaching tens of millions of untreated patients aligns commercial growth with a significant public health mission.</li>
</ul>
<br/>
